We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $8.49K invested in ELITE PHARMACEUTICAL in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

18% less capital invested

Capital invested by funds: $10.4K → $8.49K (-$1.91K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
JAFL
1
Jay A. Fishman Ltd
Michigan
$4.49K – – –
HCM
2
Highlander Capital Management
New Jersey
$4K – – –

ELI Hedge Fund Activity: Q4 2018 in Review

2 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2018, worth a combined $8.49K — down 18% from $10.4K a quarter earlier.

Fund positioning in ELI was balanced in Q4 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $8.49K of ELITE PHARMACEUTICAL stock for Q4 2018, down 18% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2018 and 0 closed out.

Based on aggregated 13F filings for Q4 2018.